hTERT gene is heavily under control of epigenetic mechanisms which regulates its transcription. This transcriptional regulation is in most cases the limiting component for telomerase activity. However, telomerase is re-activated in 85% of cancers and this re-activation of hTERT has a complex mechanism in cancers. Recently, highly frequent substitution mutations have been observed in the proximal promoter of the hTERT gene. These correlated with increased hTERT expression and telomerase activity in cancers. These mutations create de novo ETS binding motifs, which alter the chromatin organization by mediating formation of long-range chromatin interaction between hTERT promoter and distal regions of chromatin with multiple ETS binding motifs. This specific chromatin interaction alters the epigenetic features of the hTERT promoter and explains how hTERT expression is increased in cancer cells with hTERT promoter mutations.
Telomerase is a reverse transcriptase enzyme that is conserved from flagellated protozoans to higher plants and metazoans [1] . The primary function of telomerase is maintenance of chromosome ends in order to overcome DNA loss due to shortening of the lagging strand during end replication [2, 3] . Telomerase deficiencies result in shortened telomeres and significant DNA loss as a result of cell doublings and are associated with aging-related disorders. Stem cells, germ cells and some subsets of immune cells retain telomerase activity allowing them to replicate in order to give rise to progenitor cells and finally differentiated cells.
During the differentiation of stem cells to their final destination cells, the hTERT gene that codes the catalytic domain of the telomerase enzyme is transcriptionally suppressed [4] but the exact mechanism is yet to be understood.
Telomerase is re-activated in ~90% of the cancers to overcome DNA loss associated senescence and apoptosis [5] . Therefore, re-activation of telomerase is considered one of the hallmarks of cancer as it provides replicative immortality. It has been shown that all the proteins and long non-coding COMMENTARY RNA components (e.g. Terc), except the hTERT protein, from the telomerase complex are generally abundant in somatic cells. Therefore, transcription of the hTERT gene is the limiting factor for telomerase activity [6] as over-expression of hTERT is sufficient to recapitulate telomerase activity in somatic cells [7] [8] [9] . It has been shown that expression of hTERT gene is regulated by multiple mechanisms such as copy number increase, oncogene activation and differential splicing in cancer [10] . However, cancer cells have great genetic heterogeneity due to extensive genomic alterations, therefore these mechanisms are not widely applicable to all cancer cells. Better understanding the mechanisms that regulate hTERT transcription in stem cells and cancer cells is crucial to understand how telomerase is repressed in somatic cells and how it is re-activated in cancer cells. This information will help us to develop new strategies for the treatment of age related diseases and cancers.
Transcriptional regulation of a gene is a complex process that involves core promoter elements, as well as distal promoter and long-distance elements which affect the core promoter through long-range chromatin interactions [11] . The core promoter region employs basal transcription machinery, which drives expression of a gene. This is controlled by the chromatin structure in the nucleus which is tightly regulated allowing or inhibiting accessibility of the regulatory proteins to their target promoter(s) [11] . Epigenetic mechanisms including DNA methylation, histone mark occupancy, and long-range chromatin interactions regulate this accessibility of the chromatin. Nuclear organization by long-range chromatin interactions re-arrange chromatin topology according to external environmental changes or differentiation status of a cell [12] which would directly affect the transcription process. Novel techniques in next generation sequencing including chip-sequencing, chromosome conformation capture (3C), circularized chromosome conformation capture (4C), chromosome conformation capture carbon copy (5C), Hi-C and Chromatin Interaction Analysis by Paired-End Tag Sequencing (ChIA-PET) significantly advanced our understanding of how the three-dimensional organization of DNA controls gene expression together with other epigenetic factors [13] .
hTERT gene has a unique and complex promoter that is regulated epigenetically by histone modifications and DNA methylations [10] . Recently, two non-coding mutations were reported in the proximal hTERT promoter which are correlated with over-expression of the hTERT gene [14, 15] . These hTERT promoter mutations are especially common in melanoma (74%), glioblastoma (83%), hepatocellular carcinoma (44%) and urothelial bladder carcinomas (53.5%) [10] . These mutations substitute C to T and create de novo E-twenty-six (ETS) transcription factor binding motif. ETS transcription factors form homo or heterodimers for their stability to drive gene expression. GABPA, one of the ETS family members, has been shown to bind strongly to the de novo ETS motif located in the proximal hTERT promoter [16] . Reversal of the mutant hTERT promoter to wild-type reduces hTERT expression and cell growth dramatically [17, 18] . While, in in vivo experiments subcutaneously injected cancer cells with wild-type hTERT promoter showed decreased tumor growth as compared to isogenic cells of mutant hTERT promoter [18] . Interestingly, all these experiments were done in early passages of the isogenic cells which had similar telomere lengths, suggesting these effects are the result of non-canonical functions [19, 20] of hTERT on cell growth [17] . Nevertheless, in following passages of the isogenic cells, telomere length of the wild-type cells was shortened dramatically as compared to isogenic counterparts with mutant hTERT promoter cells indicating the promoter also drives the canonical function of hTERT [17] .
Recently, we identified a long-distance chromatin interaction which explains how hTERT expression is increased in cells harboring hTERT promoter mutations [17] . Cell lines with hTERT promoter mutations were corrected to wild-type sequence where the rest of the genome remained identical allowing us to investigate the long-range chromatin interaction regions with hTERT promoter region. We identified a ~2.5kb region (T-INT1), located ~300kb upstream of the hTERT promoter, harboring multiple GABPA binding motifs in its sequence. The T-INT1 region had significantly higher interaction frequency to the hTERT promoter in all the mutant cell lines when compared to their CRISPR edited isogenic wild-type counterparts. Furthermore, occupancy of active histone marks, together with binding of chromatin modifier molecule BRD4 was reduced in wild-type CRISPR edited cell lines. These results were in line with previous reports indicating that active hTERT promoter is enriched with active histone marks [21] . We showed the significance of these long-range interactions by knocking out the T-INT1 region by CRISPR/CAS9 editing strategy. We observed a dramatic reduction in hTERT expression and telomerase activity, as well as active histone marks occupancy, in the proximal hTERT promoter [17] . Importantly, removal of the T-INT1 region reduced GABPA binding in the hTERT promoter suggesting that GABPA molecules in hTERT promoter and T-INT1 region stabilize each other to drive transcription of the hTERT gene in cell lines with hTERT promoter mutation [17] . In order to investigate the impact of GABPA and BRD4 levels on the formation of long-range chromatin interactions between T-INT1 region and the hTERT promoter, we depleted GABPA and BRD4 using siRNA and observed a dramatic reduction in the formation of chromatin interactions and hTERT expression [17] . Indeed, depletion of BRD4 reduced GABPA expression, which was expected as BRD4 binds strongly to proximal GABPA promoter [17] . Since depletion of GABPA and BRD4 only had an effect on mutant hTERT promoter cells, novel BRD4 inhibitors could be used therapeutically to specifically target cancers with hTERT promoter mutations.
These results suggested that de novo ETS motif in hTERT promoter mediate long-range chromatin interaction with the T-INT1 region located ~300kb upstream of hTERT promoter. This interaction increases occupancy of active histone marks in the proximal hTERT promoter, recruiting BRD4 to the acetylated histones located in the proximal hTERT promoter. All these epigenetic changes increase the hTERT expression by recruiting Polymerase II to the hTERT transcription start site. Therefore, showing for the first time that mutant hTERT promoter is regulated by long-range chromatin interactions in cancer. However, we still do not know how hTERT expression is re-activated in the 70% of the cancers with wild-type hTERT promoter. As the hTERT promoter is capable of interacting with distal regions in the genome, it would not be surprising to find other cancer-specific chromatin interactions that re-activate the silenced hTERT promoter in cancers with wild-type hTERT promoter. It is also crucial to consider that hTERT expression is already active in stem cells; hence any further analysis of cancer cells with wild-type hTERT promoter should be conducted side by side with stem cells to identify cancer-specific activation mechanisms. Understanding of how the hTERT gene is re-activated in cancers will allow for new approaches to target telomerase in cancer. Disruption of cancer specific chromatin interactions could be a good option, as these interactions do not form in the stem cell compartment or in normal cells. Therefore, inhibiting molecules responsible for the formation of these specific chromatin interactions will specifically inhibit hTERT expression and cell growth in cancer cells.
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